These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 31695807)

  • 1. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy.
    Lim S; Park J; Shim MK; Um W; Yoon HY; Ryu JH; Lim DK; Kim K
    Theranostics; 2019; 9(25):7906-7923. PubMed ID: 31695807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle mediated cancer immunotherapy.
    Gupta J; Safdari HA; Hoque M
    Semin Cancer Biol; 2021 Feb; 69():307-324. PubMed ID: 32259643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy.
    Gao J; Wang WQ; Pei Q; Lord MS; Yu HJ
    Acta Pharmacol Sin; 2020 Jul; 41(7):986-994. PubMed ID: 32317755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancements in nanomedicine delivery systems: unraveling immune regulation strategies for tumor immunotherapy.
    Zhang Y; Chen X; Hu B; Zou B; Xu Y
    Nanomedicine (Lond); 2024; 19(21-22):1821-1840. PubMed ID: 39011582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy.
    Zhao X; Yang K; Zhao R; Ji T; Wang X; Yang X; Zhang Y; Cheng K; Liu S; Hao J; Ren H; Leong KW; Nie G
    Biomaterials; 2016 Sep; 102():187-97. PubMed ID: 27343466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticles for tumor immunotherapy.
    Zang X; Zhao X; Hu H; Qiao M; Deng Y; Chen D
    Eur J Pharm Biopharm; 2017 Jun; 115():243-256. PubMed ID: 28323111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy.
    Musetti S; Huang L
    ACS Nano; 2018 Dec; 12(12):11740-11755. PubMed ID: 30508378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle Delivery of Immunostimulatory Agents for Cancer Immunotherapy.
    Zhuang J; Holay M; Park JH; Fang RH; Zhang J; Zhang L
    Theranostics; 2019; 9(25):7826-7848. PubMed ID: 31695803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-based nanosystems: the next generation of cancer immune therapy.
    Cheng Z; Fobian SF; Gurrieri E; Amin M; D'Agostino VG; Falahati M; Zalba S; Debets R; Garrido MJ; Saeed M; Seynhaeve ALB; Balcioglu HE; Ten Hagen TLM
    J Hematol Oncol; 2024 Jul; 17(1):53. PubMed ID: 39030582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy.
    Duan X; Chan C; Lin W
    Angew Chem Int Ed Engl; 2019 Jan; 58(3):670-680. PubMed ID: 30016571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy.
    Jiang Z; Zhang W; Zhang J; Liu T; Xing J; Zhang H; Tang D
    Int J Nanomedicine; 2022; 17():4677-4696. PubMed ID: 36211025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery strategies of cancer immunotherapy: recent advances and future perspectives.
    Zhao Z; Zheng L; Chen W; Weng W; Song J; Ji J
    J Hematol Oncol; 2019 Nov; 12(1):126. PubMed ID: 31779642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy.
    Huang L; Huang Z; Zhang Y; Lin C; Zhao Z; Li R; Saw PE; Xu X
    Theranostics; 2024; 14(14):5528-5550. PubMed ID: 39310113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Nanoparticle-Based Targeted Drug-Delivery Systems Against Cancer and Role of Tumor Microenvironment.
    Ashfaq UA; Riaz M; Yasmeen E; Yousaf MZ
    Crit Rev Ther Drug Carrier Syst; 2017; 34(4):317-353. PubMed ID: 29199588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of nanotechnology in circumventing immunotolerance.
    Ma Y; Shen Y; Zhu B; Li D; Liu J
    Pharmazie; 2020 Oct; 75(10):470-477. PubMed ID: 33305719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanovaccines: Immunogenic tumor antigens, targeted delivery, and combination therapy to enhance cancer immunotherapy.
    Jahanafrooz Z; Oroojalian F; Mokhtarzadeh A; Rahdar A; Díez-Pascual AM
    Drug Dev Res; 2024 Aug; 85(5):e22244. PubMed ID: 39138855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors.
    Qian X; Shi Z; Qi H; Zhao M; Huang K; Han D; Zhou J; Liu C; Liu Y; Lu Y; Yuan X; Zhao J; Kang C
    Theranostics; 2019; 9(25):7616-7627. PubMed ID: 31695790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy.
    Han S; Huang K; Gu Z; Wu J
    Nanoscale; 2020 Jan; 12(2):413-436. PubMed ID: 31829394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Delivery for Cancer Immunotherapy and Vaccines.
    Batty CJ; Tiet P; Bachelder EM; Ainslie KM
    Pharm Nanotechnol; 2018; 6(4):232-244. PubMed ID: 30227827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy.
    Zhou L; Zhang P; Wang H; Wang D; Li Y
    Acc Chem Res; 2020 Sep; 53(9):1761-1772. PubMed ID: 32819102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.